The Accreditation for Cardiovascular Excellence (ACE) announced this week that updated standards for cardiac intervention procedures have been published and are now available for download on the ACE website. ACE updated its Cath/PCI standards to align with the recently published clinical competency document for PCI which includes information on physician training, clinical competency criteria and the updated expert consensus document published in 2012.

The University of Vermont College of Medicine has announced that cardiologist and Professor of Medicine David Schneider, M.D., has been appointed director of the Cardiovascular Research Institute (CVRI). The director of cardiology in the department of medicine and medical director of cardiology at Fletcher Allen Health Care, Schneider will succeed CVRI founding director Burton Sobel, M.D., who passed away in spring 2013.

Through the kindness of Richard M. and Yvonne Hamlin, Summa Health System announced today the largest philanthropic gift in its organization’s history – a $4 million contribution for the creation of a hybrid cardiovascular operating room at Summa Akron City Hospital. In honor of the benefactors, Summa’s Center of Excellence building at 95 Arch Street in Akron will be renamed The Richard M. and Yvonne Hamlin Pavilion. The facility is home to numerous cardiopulmonary patient services as well as medical and surgical physician offices.

To improve clinical staff safety during interventional procedures and help monitor radiation dose, Toshiba America Medical Systems, Inc. has partnered with Unfors RaySafe, Inc. to offer a new dose monitoring and management tool for Infinix™-i cardiovascular X-ray systems. The Unfors RaySafe i2 displays real-time dose exposure information, helping to make exams safer for all clinical staff.

Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration 510(k) clearance and CE Mark approval for the Guidezilla™ Guide Extension Catheter and has launched the device in the U.S. and Europe.

STENTYS, a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), announced today that it received approval from its European Notified Body to expand the CE Mark indications of the Self-Apposing stent.

ATLANTA—Opportunities exist within many cardiovascular programs to trim out costs and add value. But where? Suzette Jaskie, president and CEO of MedAxiom Consulting, offered five “slam dunk” approaches June 13 at the Cardiovascular Service Line Symposium in Atlanta.

The delayed healing of the coronary artery following physicians’ use of drug eluting stents (DES), which increases patients’ risks of developing thrombosis, is a top concern today of interventional cardiologists, according to the results of a survey announced at EuroPCR 2013 in Paris.